iBio, Inc. (NYSEMKT:IBIO – Get Free Report) fell 2.9% on Thursday . The company traded as low as $4.39 and last traded at $4.39. 321,644 shares were traded during trading, an increase of 184% from the average session volume of 113,212 shares. The stock had previously closed at $4.52.
iBio Price Performance
The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $3.92 and a two-hundred day simple moving average of $2.95.
About iBio
iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
Featured Articles
- Five stocks we like better than iBio
- How to Start Investing in Real Estate
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- What is Put Option Volume?
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- What Are Earnings Reports?
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
